New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
08:48 EDTFMIFoundation Medicine data to have positive effect on reimbursement, says Wedbush
After clinical data on gene fusion detection indicated that such detection led to clinical action in about 15% of patients, Wedbush thinks the 15% level will be more than enough for large payors to recognize the importance of deep tumor profiling in some patients. The firm thinks the recent increase in reimbursement rates for BRCA pricing is positive for long-term FoundationOne reimbursement. Wedbush keeps a $50 price target and Outperform rating on Foundation Medicine.
News For FMI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 22, 2014
08:22 EDTFMIFoundation Medicine, WuXi PharmaTech announce strategic collaboration
Foundation Medicine (FMI) and WuXi PharmaTech (WX) announced a collaboration to offer Foundation Medicine’s comprehensive genomic profiling to biopharmaceutical companies conducting clinical trials in China. Under the terms of the collaboration, Foundation Medicine will license and enable WuXi to perform the laboratory component of Foundation Medicine’s FoundationOne assay at the WuXi Genome Center in Shanghai, the first and only CLIA-certified laboratory in China. Foundation Medicine will offer China-based products and services to global biopharmaceutical partners to support their clinical research and development efforts in China. Financial terms of the collaboration are not being disclosed.
08:13 EDTFMIFoundation Medicine, WuXi PharmaTech announce collaboration
Subscribe for More Information
October 17, 2014
06:31 EDTFMIFoundation Medicine upgraded to Outperform from Market Perform at William Blair
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use